Five cases of Plasmodium vivax malaria treated with artemisinin derivatives: the advantages of a unified approach to treatment.
Artemisinin combination therapy (ACT)
Chloroquine resistance
Imported malaria
Plasmodium vivax
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
11
10
2018
accepted:
19
02
2019
pubmed:
28
2
2019
medline:
13
11
2019
entrez:
28
2
2019
Statut:
ppublish
Résumé
In endemic countries with a high level of chloroquine resistance, Plasmodium vivax malaria is associated with high morbidity and mortality. In these areas, the dihydroartemisinin-piperaquine combination resulted in clinical response, a more rapid clearance of parasitaemia, compared to chloroquine therapies, and reduction of recrudescence or reinfection. We describe five cases of Plasmodium vivax malaria in returning travelers treated with dihydroartemisinin-piperaquine. All patients showed the early parasite clearance and no side effects. Our preliminary results suggest that the dihydroartemisinin-piperaquine combination is effective and safe even in imported cases. A unified treatment policy using the artemisinin combination therapy should be adopted even in non-endemic countries and larger studies are underway to support this strategy.
Identifiants
pubmed: 30809760
doi: 10.1007/s15010-019-01286-6
pii: 10.1007/s15010-019-01286-6
doi:
Substances chimiques
Antimalarials
0
Artemisinins
0
artenimol
6A9O50735X
Primaquine
MVR3634GX1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
655-659Subventions
Organisme : Ministero della Salute
ID : Ricerca Corrente
Références
Clin Infect Dis. 1999 May;28(5):1182-3
pubmed: 10452670
Am J Trop Med Hyg. 2002 Sep;67(3):230-2
pubmed: 12408660
Lancet. 2007 Mar 3;369(9563):757-765
pubmed: 17336652
PLoS Med. 2008 Jun 17;5(6):e128
pubmed: 18563962
Lancet Infect Dis. 2009 Sep;9(9):555-66
pubmed: 19695492
Lancet Infect Dis. 2010 Jun;10(6):405-16
pubmed: 20510281
Clin Infect Dis. 2011 Nov;53(10):977-84
pubmed: 22002979
Malar J. 2012 Sep 17;11:328
pubmed: 22985344
Antimicrob Agents Chemother. 2013 Feb;57(2):818-26
pubmed: 23208711
Malar J. 2013 Jan 08;12:8
pubmed: 23294844
Cochrane Database Syst Rev. 2013 Oct 25;(10):CD008492
pubmed: 24163021
PLoS One. 2013 Dec 03;8(12):e78819
pubmed: 24312446
PLoS Med. 2013 Dec;10(12):e1001575; discussion e1001575
pubmed: 24358031
PLoS Negl Trop Dis. 2014 Aug 14;8(8):e3071
pubmed: 25121491
Lancet Infect Dis. 2014 Oct;14(10):982-91
pubmed: 25213732
Antimicrob Agents Chemother. 2015 Jan;59(1):730-3
pubmed: 25385109
Malar J. 2014 Nov 26;13:463
pubmed: 25428624
J Infect. 2016 Jun;72(6):635-649
pubmed: 26880088
Infection. 2017 Feb;45(1):111-114
pubmed: 27565658
Am J Trop Med Hyg. 2018 Feb;98(2):543-550
pubmed: 29280424
Infection. 2018 Dec;46(6):867-870
pubmed: 29980936
Lancet Infect Dis. 2018 Sep;18(9):1025-1034
pubmed: 30033231
Malar J. 2018 Oct 5;17(1):350
pubmed: 30290825